glp-1 agonists: Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor A Scoping Review The Impact of GLP-1 Receptor

This analytical review critically examines the evidence surrounding GLP-1 agonists efficacy, safety, and real-world implications for obesity treatment in individuals without diabetes

Discover the research, how they work, who should try these, and more.

New research indicates that maintaining meaningful weight loss after starting GLP-1-based therapies could play an important role in reducing the risk of multiple obesity-related diseases.

Other oral compounds like CT-996 / RG 6652 showed a clinically meaningful weight reduction of 6-7% in four weeks among participants without T2D, and GSBR-1290 has demonstrated favourable safety, tolerability and efficacy results

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

Were now seeing a real shift: from weekly injections to once-daily pills Two oral GLP-1 options are now leading this transition: #Wegovy pill (oral semaglutide) first to market #Foundayo (orforglipron) newest entrant But heres what you must know